ODM-207
BET inhibitor
Also Known As:
6-(3,5-dimethylisoxazol-4-yl)-7-methoxy-3-methyl-1-(pyridin-2-ylmethyl)quinolin-2(1H)-one
Networked: 2
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Ameratunga, Malaka:
1 article
(12/2020)
|
| 2. | Aspegren, John:
1 article
(12/2020)
|
| 3. | Bono, Petri:
1 article
(12/2020)
|
| 4. | Braña, Irene:
1 article
(12/2020)
|
| 5. | Korjamo, Timo:
1 article
(12/2020)
|
| 6. | Plummer, Ruth:
1 article
(12/2020)
|
| 7. | Postel-Vinay, Sophie:
1 article
(12/2020)
|
| 8. | Snapir, Amir:
1 article
(12/2020)
|
| 9. | de Bono, Johann S:
1 article
(12/2020)
|
| 10. | Han, Jie:
1 article
(01/2020)
|
Related Diseases
| 1. | Hematologic Neoplasms (Hematological Malignancy)
01/01/2020
- " Methods: We retrieved and reviewed published reports on the clinical trials of twelve BET inhibitors including AZD5153, ABBV-075, BMS-986158, CPI-0610, GSK525762, OTX-015, PLX51107, INCB054329, INCB057643, FT-1101, CC-90010, and ODM-207 for patients with hematological malignancies and solid tumors and summarized their published target genes. "
|
| 2. | Neoplasms (Cancer)
01/01/2020
- " Methods: We retrieved and reviewed published reports on the clinical trials of twelve BET inhibitors including AZD5153, ABBV-075, BMS-986158, CPI-0610, GSK525762, OTX-015, PLX51107, INCB054329, INCB057643, FT-1101, CC-90010, and ODM-207 for patients with hematological malignancies and solid tumors and summarized their published target genes. "
|
| 3. | Prostatic Neoplasms (Prostate Cancer)
|
|
Related Drugs and Biologics